CBST

{"sector":"Healthcare","industry":"Drugs","symbol":"CBST","company_name":"Cubist Pharmaceuticals","exchange":"NASDAQ"}

CBST Articles

Merck shares posted a new 52-week high last Tuesday and closed Friday less than a buck from that high. Year to date, Its shares are up 11%.
One key consideration for the year ahead is Merck's acquisitions of Idenix and Cubist Pharmaceuticals to expand its product offerings
SunTrust Robinson Humphrey analysts say in a research note that Achaogen and Cempra could be in play as acquisition targets.
Merck will acquire Cubist for $102 a share, or, about $9.5 billion, including $1.1 billion in Cubist’s net debt and other items.
At least five upcoming dates could be big days in December, for better or worse, for individual biotech stocks.
Thursday's top analyst upgrades, downgrades and initiations include American Express, Apache, Cliffs Natural Resources, Denbury Resources, JetBlue Airways and Synchrony Financial.
These are the top analyst upgrades, downgrades and initiations from Wall Street firms for Wednesday, July 23, 2014. They include DuPont, General Electric, King, Microsoft, Xilinx and McDonald's.
Source: ThinkstockEarnings season is now well under way for the second quarter. So far, things are looking good. The biotech sector has yet to see any significant earnings representation. That will...
Source: ThinkstockOne of the main concerns physicians have agreed upon in recent years has been the overuse of antibiotics by some health care professionals. Their overuse in some cases has led many...
24/7 Wall St. wanted to evaluate the prospects for several would-be blockbuster drugs. Some of these have approvals already in hand, while others have pending FDA approval verdicts.
In a new research report, Jefferies highlights stocks that may exceed earnings estimates when the companies report in the next few weeks. These stocks could move up nicely on a surprise.
In a new research report, the boutique firm Leerink highlights 10 top biotech names that are strong candidates for a partnership or acquisition. Any of these picks may be a great addition for...
Source: ThinkstockThe world of biotechnology investing is a constantly evolving and changing one. While disease for the most part does not change all that much, the manner in which it can be treated...
Source: Jon OggEarnings season has just started, and investors and traders alike are having to face a government shutdown and a debt ceiling debate painfully developing each day. So which companies...
Source: Jon OggStocks have seen five days of selling, and investors are deciding which stocks are bargains and which ones will have more downside. 24/7 Wall St. reviews dozens of Wall Street analyst...